Package leaflet: Information for the user

Zoledronic acid 4 mg/5 ml concentrate for solution for infusion

Zoledronic acid

Read all of this leaflet carefully before you are given Zoledronic acid because it contains important information for you.

•    Keep this leaflet. You may need to read it again.

•    If you have any further questions, ask your doctor, nurse or pharmacist.

•    If you get any side effects , talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

What is in this leaflet

1.    What Zoledronic acid is and what it is used for

2.    What you need to know before you are given Zoledronic acid

3.    How Zoledronic acid is used

4.    Possible side effects

5.    How to store Zoledronic acid

6.    Contents of the pack and other information

1. What Zoledronic acid is and what it is used for

The active substance in Zoledronic acid is zoledronic acid, which belongs to a group of substances called bisphosphonates. Zoledronic acid works by attaching itself to the bone and slowing down the rate of bone change. It is used:

•    To prevent bone complications eg. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).

•    To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour. Tumours can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumour-induced hypercalcaemia (TIH).

2. What you need to know before you are given Zoledronic acid

3. How Zoledronic acid is used

Zoledronic acid must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.

Your doctor will recommend that you drink enough water before each treatment to help prevent dehydration.

Carefully follow all the other instructions given to you by your doctor, nurse or pharmacist.

How much Zoledronic acid is given

•    The usual single dose given is 4 mg.

•    If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.

How often Zoledronic acid is given

•    If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zoledronic acid every three to four weeks.

•    If you are being treated to reduce the amount of calcium in your blood, you will normally only be given one infusion of Zoledronic acid.

How Zoledronic acid is given

Zoledronic acid is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.

Patients whose blood calcium levels are not too high will also be prescribed calcium and vitamin D supplements to be taken each day.

If you are given more Zoledronic acid than you should be

If you have received doses higher than those recommended, you must be carefully monitored by your doctor. This is because you may develop serum electrolyte abnormalities (e.g. abnormal levels of calcium, phosphorus and magnesium) and/or changes in kidney function, including severe kidney impairment. If your level of calcium falls too low, you may have to be given supplemental calcium by infusion.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

Follow carefully all instructions given to you by your doctor.

Your doctor will carry out blood tests before you start treatment with Zoledronic acid and will check your response to treatment at regular intervals.

You should not be given Zoledronic acid

•    if you are allergic (hypersensitive) to zoledronic acid, another bisphosphonate (the group of substances to which Zoledronic acid belongs), or any of the other ingredients of Zoledronic acid (see section 6).

•    if you are breast-feeding.

Before you are given Zoledronic acid, tell your doctor

•    if you have or have had a kidney problem.

•    if you have or have had pain, swelling or numbness

of the jaw, a feeling of heaviness in the jaw or loosening of a tooth.

•    if you are having dental treatment or are due to undergo dental surgery, tell your dentist that you are being treated with Zoledronic acid.

Other medicines and Zoledronic acid

Tell your doctor if you are taking, have recently taken or might take any other medicines. It is especially important that you tell your doctor if you are also taking:

•    Aminoglycosides (medicines used to treat severe infections), since the combination of these with bisphosphonates may cause the calcium level in the blood to become too low.

•    Thalidomide (a medicine used to treat a certain type of blood cancer involving the bone) or any other medicines which may harm your kidneys.

•    Medicines that also contain zoledronic acid used to treat osteoporosis and other non-cancer diseases of the bone, or any other bisphosphonate, since the combined effects of these medicines taken together with zoledronic acid are unknown.

•    Anti-angiogenic medicines (used to treat cancer), since the combination of these with zoledronic acid has been associated with reports of osteonecrosis of the jaw (ONJ).

Patients aged 65 years and over

Zoledronic acid can be given to people aged 65 years and over. There is no evidence to suggest that any extra precautions are needed.

Children and adolescents

Zoledronic acid is not recommended for use in adolescents and children below the age of 18 years.

Pregnancy and breast-feeding

You should not be given Zoledronic acid if you are pregnant. Tell your doctor if you are or think that you may be pregnant.

You must not be given Zoledronic acid if you are breast-feeding.

Ask your doctor for advice before taking any medicine while you are pregnant or breast-feeding.

Driving and using machines

There have been very rare cases of drowsiness and sleepiness with the use of zoledronic acid. You should therefore be careful when driving, using machinery or performing other tasks that need full attention.

Zoledronic acid contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially "sodium-free".

Like all medicines, this medicine can cause side effects, although not everybody gets them. The most common ones are usually mild and will probably disappear after a short time.

Tell your doctor about any of the following serious side effects straight away:

Common (may affect up to 1 in 10 people):

•    Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests).

•    Low level of calcium in the blood.

Uncommon (may affect up to 1 in 100 people):

•    Pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. These could be signs of bone damage in the jaw (osteonecrosis). Tell your doctor and dentist immediately if you experience such symptoms.

•    Irregular heart rhythm (atrial fibrillation) has been seen in patients receiving zoledronic acid for postmenopausal osteoporosis. It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received zoledronic acid.

•    Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.

Tell your doctor about any of the following side effects as soon as possible:

Very common (may affect more than 1 in 10 people):

•    Low level of phosphate in the blood.

Common (may affect up to 1 in 10 people):

•    Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/ or muscle ache. In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days).

•    Gastrointestinal reactions such as nausea vomiting as well as loss of appetite.

•    Conjunctivitis

•    Low level of red blood cells (anaemia).

Uncommon (may affect up to 1 in 100 people):

•    Allergic (hypersensitivity) reactions

•    Low blood pressure

•    Chest pain

•    Skin reactions (redness and swelling) at the infusion site, rash, itching

•    High blood pressure

•    Shortness of breath

•    Dizziness

•    Sleep disturbances

•    Tingling or numbness of the hands or feet

•    Diarrhoea

•    Low counts of white blood cells and blood platelets

•    Low level of magnesium and potassium in the blood. Your doctor will monitor this and take any necessary measures

•    Sleepiness.

•    Tearing of the eye, eye sensitivity to light.

•    Sudden coldness with fainting, limpness or collapse.

•    Difficulty in breathing with wheezing or coughing.

•    Urticaria.

The following information is intended for healthcare professionals only

How to prepare and administer Zoledronic acid

- To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic acid concentrate (5.0 ml) with 100 ml of calcium-free or other divalent cation-free infusion solution. If a lower dose of Zoledronic acid is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution. To avoid potential incompatibilities, the infusion solution used for dilution must be either 0.9% w/v sodium chloride or 5% w/v glucose solution.

Do not mix Zoledronic acid concentrate with calcium-containing or other divalent cation containing solutions such as lactated Ringer's solution.

Instructions for preparing reduced doses of Zoledronic acid: Withdraw the appropriate volume of the liquid concentrate,

as follows:

-    4.4 ml for 3.5 mg dose

-    4.1 ml for 3.3 mg dose

-    3.8 ml for 3.0 mg dose

-    For single use only. Any unused solution should be discarded. Only clear solution free from particles and discolouration should be used. Aseptic techniques must be followed during the preparation of the infusion.

-    Shelf life after dilution: chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8°C. From a microbiological point of view, the diluted solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C. The refrigerated solution should then be equilibrated to room temperature prior to administration.

V001

M087454/00 UK/IE

Rare (may affect up to 1 in 1,000 people):

•    Slow heart beat

•    Confusion

•    Unusual fracture of the thigh bone particularly in patients on long-term treatment for osteoporosis may occur rarely. Contact your doctor if you experience pain, weakness or discomfort in your thigh, hip or groin as this may be an early indication of a possible fracture of the thigh bone.

Spain    Acido Zoledronico Fresenius    Kabi

4 mg / 5 ml concentrado para solucion para perfusion

Sweden    Zoledronsyra Fresenius Kabi

United Kingdom Zoledronic acid 4 mg/5 ml concentrate for solution for infusion

This leaflet was last revised in 08/2012.

Very rare (may affect up to 1 in 10,000 people):

•    Fainting due to low blood pressure

•    Severe bone, joint and/or muscle pain, occasionally incapacitating

•    Painful redness and/or swelling of the eye

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.

5.    How to store Zoledronic acid

Your doctor, nurse or pharmacist knows how to store Zoledronic acid properly (see section 6).

6.    Contents of the pack and other information

What Zoledronic acid contains

•    The active substance of Zoledronic acid is zoledronic acid. One vial contains 4 mg of zoledronic acid (as monohydrate).

•    The other ingredients are: mannitol, sodium citrate, water for injections.

What Zoledronic acid looks like and contents of the pack

Zoledronic acid is supplied as a solution in a clear and colourless plastic vial.

Zoledronic acid is supplied as packs containing 1,4 or 10 vials. Not all pack sizes may be marketed.

Marketing Authorisation Holder

Fresenius Kabi Limited Cestrian Court, Eastgate Way,

Manor Park, Runcorn,

Cheshire, WA7 1 NT,

United Kingdom

Manufacturer

Fresenius Kabi Austria GmbH,

Hafnerstrasse 36,

A-8055 Graz,

Austria

This medicinal product is authorised in the Member States of the EEA under the following names:

-    The solution containing Zoledronic acid is given as a single 15 minute intravenous infusion in a separate infusion line. The hydration status of patients must be assessed prior to and following administration of Zoledronic acid to ensure that they are adequately hydrated.

-    Studies with glass bottles, as well as several container types made from polyvinylchloride, polyethylene and polypropylene (prefilled with 0.9% w/v sodium chloride solution or 5% w/v glucose solution) showed no incompatibility with Zoledronic acid.

-    Since no data are available on the compatibility of Zoledronic acid with other intravenously administered substances, Zoledronic acid must not be mixed with other medications/substances and should always be given through a separate infusion line.

How to store Zoledronic acid

-    Keep Zoledronic acid out of the sight and reach of children.

-    Do not use Zoledronic acid after the expiry date stated on the pack.

-    The unopened vial does not require any specific storage conditions.

-    For storage conditions after dilution, see "Shelf life after dilution"

FRESENIUS

KABI